New pharmacological treatments for urinary incontinence and overactive bladder

Current Opinion in Investigational Drugs

Volumn 6, Issue 1, 2005, Pages 81-89

  Burgard, Edward C ^a   Fraser, Matthew O ^a   Karicheti, Venkateswarlu ^a   Ricca, Daniel J ^a   Thor, Karl B ^a  

^a Dynogen Pharmaceuticals Inc   (United States)

Author keywords

Benign prostatic hyperplasia; Detrusor instability; Interstitial cystitis; Lower urinary tract; Micturition; Neurogenic bladder; Stress incontinence; Urge incontinence

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BESIPIRDINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAPSAICIN; CIZOLIRTINE; DABUZALGRON; DARIFENACIN; DESMOPRESSIN; DULOXETINE; FINASTERIDE; FLURBIPROFEN 4 NITROXYBUTYL ESTER; MUSCARINIC RECEPTOR BLOCKING AGENT; N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE; NORADRENALIN UPTAKE INHIBITOR; OPIATE AGONIST; OXYBUTYNIN; PHENYLPROPANOLAMINE; POTASSIUM CHANNEL STIMULATING AGENT; RESINIFERATOXIN; SEROTONIN UPTAKE INHIBITOR; SILODOSIN; SOLIFENACIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TACHYKININ RECEPTOR ANTAGONIST; TALNETANT; TEMIVERINE; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG ABUSE; DRUG APPROVAL; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHORIA; FIRST PASS EFFECT; HUMAN; NONHUMAN; OVERACTIVE BLADDER; PROSTATE HYPERTROPHY; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; URETHRA DISEASE; URGE INCONTINENCE; URINE INCONTINENCE; VASCULAR DISEASE; XEROSTOMIA;

ANIMALS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; NEUROTRANSMITTER AGENTS; RECEPTORS, DRUG; URINARY INCONTINENCE;

EID: 12544253235     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. de Groat WC, Yoshimura N: Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol (2001) 41 691-721.
2. Fraser MO, Burgard EC, Thor KB: Urinary incontinence: Neuropharmacological approaches. In: Annual Reports in Medicinal Chemistry. Robertson (Eds), Elsevier Press, New York, NY, USA (2004) 38:51-60.
3. Morrison J, Steers WD, Brading A, Blok B, Fry C, deGroat WC, Kakizaki H, Levin R, Thor K: Neurophysiology and Neuropharmacology. In: Incontinence. Abrams P, Cardozo L, Khoury S, Wein A (Eds), Health Publication Ltd, Plymouth, UK (2002 ):83-163.
4. Yoshimura N, Seki S, Chancellor MB, de Groat WC, Ueda T: Targeting afferent hyperexcitability for therapy of the painful bladder syndrome. Urology (2002) 59(5 Suppl 1):61-67.
5. Hegde SS, Mammen M, Jasper JR: Antimuscarinics for the treatment of overactive bladder: Current options and emerging therapies. Curr Opin Investig Drugs (2004) 5(1):40-49.
6. Fraser MO, Lavelle JP, Sacks MS, Chancellor MB: The future of bladder control - intravesical drug delivery, a pinch of pepper, and gene therapy. Rev Urol (2002) 4(1):1-11.
7. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol (2004) 45 4):420-429.
8. Hamada K, Sasaki Y, Taniguchi N, Fukui H, Miyatsuka Y, Kimura Y, Ukai Y, Yoshikuni Y, Kimura K: Anticholinergic and calcium antagonistic activities of NS-21 contribute to the inhibition of rat urinary bladder contractions. Gen Pharmacol (1997) 29 5):771-778.
9. Sorbera LA, Czotaner J, Leesan PA: Fesoterodine. Drugs Future (2003) 28(7):647.
10. Miyachi H, Kiyota H, Uchiki H, Segawa M: Synthesis and antimuscarinic activity of a series of 4-(1-imidazolyl)-2,2-diphenylbutyramides: Discovery of potent and subtype-selective antimuscarinic agents. Bioorg Med Chem (1999) 7(6):1151-1161.
11. First-Third Ouarter (April 1-December 31 2003) Flash Report. Ono Pharmaceuticals Co Ltd (2004). http://www.ono.co.jp/jp/ir_info/annual/pdf/2004/i0402.pdf
12. Jacobs BL, Martin-Cora FJ, Fornal CA: Activity of medullary serotonergic neurons in freely moving animals. Brain Res Brain Res Rev (2002) 40(1-3):45-52.
13. Jacobs BL, Abercrombie ED, Fornal CA, Levine ES, Morilak DA, Stafford IL: Single-unit and physiological analyses of brain norepinsphrine function in behaving animals. Prog Brain Res (1991) 88:159-165.
14. Burgard EC, Fraser MO, Thor KB: Serotonergic modulation of bladder afferent pathways. Urology (2003) 62(4 Suppl 1):10-15.
15. Thor KB, Katofiasc MA: Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther (1995) 274(2 ):1014-1024.
16. Norton PA, Zinner NR, Yalcin I, Bump RC: Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol (2002) 187(1):40-48.
17. Sterner O, Szallasi A: Novel natural vanilloid receptor agonists: New therapeutic targets for drug development. Trends Pharmacol Sci (1999) 20(11):459-465.
18. de Seze M, Wiart L, de Seze MP, Soyeur L, Dosque JP, Blajezewski S, Moore N, Brochet B, Mazaux JM, Barat M, Joseph PA: Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: A double-blind, randomized, controlled study. J Urol (2004) 171 1):251-255.
19. Lazzeri M, Spinelli M, Zanollo A, Turini D: Intravesical vanilloids and neurogenic incontinence: Ten years experience. Urol Int (2004) 72(2):145-149.
20. Silva C, Ribeiro MJ, Cruz F: The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol (2002) 168(2):575-579.
21. Icos Corporation: ICOS Corporation reports results for 2003. Press Release (2004): February 3. http://media.corporate-ir.net/media_files/nsd/icos/news /PR_Q403_ICOS.pdf
22. Thorpe A, Neal D: Benign prostatic hyperplasia. Lancet (2003) 361(9366):1359-1367.
23. 1A-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther (1999) 291(1):81-91.
24. Annual Report 2003: Kissei Pharmaceutical Co Ltd, Nagano, Japan. Kissei Pharmaceutical Co Ltd (2004). http://www.kissei.co.jp/e_contents/pdf/kissei_ar2003.pdf
25. Klussmann E, Maric K, Rosenthal W: The mechanisms of aquaporin control in the renal collecting duct. Rev Physiol Biochem Pharmacol (2000) 141:33-95.
26. Hoverd PA, Fowler CJ: Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatr (1998) 65(5):778-780.
27. Pipeline: Otsuka Maryland Research Institute, Maryland, USA. Otsuka Maryland Research Institute (2004). http://www.otsuka.com/OMRI/othertherapeutic.htm.
28. 2-receptor agonist, OPC-51803, administered orally to rats. J Pharmacol Exp Ther (2000) 295(3 ):1005-1011.
29. Bramer SL, Zhu Z, Brisson J, Bricmon P: Pharmacokinetics (PK) and pharmacodynamics (PD) of OPC-51803 in adult patients with urinary incontinence. Clin Pharmacol Ther (2002) 71(2 :Abs MPI-97.
30. + channels in the urinary bladder of the guinea pig. Pharmacology (1996) 53(3 ):170-179.
31. ATP channel opener with in vivo selectivity for urinary bladder. J Pharmacol Exp Ther (1995) 274(2):884-890.
32. Abdel-Karim AM, Bialecki RA, Elhilali MM: Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats. J Urol (2002) 168 2):837-842.
33. Development Pipeline: AstraZeneca, Massachusetts, USA. AstraZeneca plc (2004). http://www.astrazeneca.com/sites/7/imagebank/typearticleparam501216 /Development%20Pipeline_feb04.pdf
34. Tanaka M, Sasaki Y, Kimura Y, Fukui T, Hamada K, Ukai Y: A novel pyrrole derivative, NS-8 suppresses the rat micturition reflex by inhibition afferent pelvic nerve activity. Br J Urol Int (2003) 92(9):1031-1036.
35. News, November 4, 2003: Nippon Shinyaku, Tokyo, Japan. Nippon Shinyaku Co Ltd (2004). http://www.nippon-shinyaku.co.jp/english/ns01/2003/110403.html
36. + currents in neurons of the dorsal root ganglion of the adult rat. J Pharmacol Exp Ther (2004) 310(1):159-168.
37. Lu SH, Yamagata T, Atsuki K, Sun L, Smith CP, Yoshimura N, Chancellor MB, de Groat WC: Effect of KW-7158, a putative afferent nerve inhibitor, on bladder and vesico-vascular reflexes in rats. Brain Res (2002) 946(1):72-78.
38. R&D pipelines: Kyowa Hakko, Tokyo, Japan. Kyowa Hakko Kogyo Co Ltd (2004). http://www.kyowa.co.jp/eng/company/iyaku/pdf/rd_pipeline.pdf
39. de Groat WC, Kawatani M, Hisamitsu T, Lowe I, Morgan C, Roppolo J, Booth AM, Nadelhaft I, Kuo D, Thor K: The role of neuropeptides in the sacral autonomic reflex pathways of the cat. J Auton Nerv Syst (1983) 7(3-4):339-350.
40. Thor KB, Hisamitsu T, Roppolo JR, Tuttle P, Nagel J, de Groat WC: Selective inhibitory effects of ethylketocyclazocine on reflex pathways to the external urethral sphincter of the cat. J Pharmacol Exp Ther (1989) 248(3):1018-1025.
41. Products: Ardent Pharmaceuticals Inc, North Carolina, USA. Ardent Pharmaceutical Inc (2004). http://www.ardentpharma.com/products.asp
42. Lazzeri M, Calo G, Spinelli M, Guerrini R, Salvadori S, Beneforti P, Sandri S, Regoli D, Turini D: Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic destrusor overactivity: A randomized, placebo-controlled, double-blind study. Eur Urol Suppl (2003) 2(1):Abs 277.
43. Kamo I, Doi T: Effect of TAK-637, a tachykinin NK1-receptor antagonist, on lower urinary tract function in cats. Jpn J Pharmacol (2001) 86(2):165-169.
44. Development Achievement & Status FY2003. Takeda Chemical Indusctries Ltd, Osaka, Japan. Takeda Chemical Industries Ltd (2004). http://www.takeda.co.jp/english/financial/imeeting2004t/pdf/03.pdf
45. Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME, Elshourbagy NA, Medhurst AD, Giardina GA, Hay DW: Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther (1997) 281(3):1303-1311.
46. Product pipeline: GlaxoSmithKline. GlaxoSmithKline Inc (2004). http://science.gsk.com/pipeline/index.htm
47. 3-adtrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol (2001) 166(3):1142-1147.
48. 3-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. J Pharmacol Exp Ther (2000) 293(3 ):939-945.
49. 3-adrenoceptor agonist on bladder function in rats. Annual Meeting of International Continence Society, Heidelberg, Germany (2002)32:Abs 95.
50. News Centre 29 November 2002; Boehringer Ingelheim GmbH, Germany. Boehringer Ingelheim GmbH (2004). http://www.boehringer-ingelheim.com/corporate/asp/archive /adetail.asp?ID=426
51. Overview of Product Pipeline: Yamanouchi Pharmaceutical Co Ltd, Japan. Yamanouchi Pharmaceutical Co Ltd (2004). http://www.yamanouchi.com/eg/ir/fi/fi405/english_pipeline2004.pdf
52. Product pipeline: GlaxoSmithKline GlaxoSmithKline Inc (2004). http://science.gsk.com/pipeline/index.htm
53. Alhasso A, Glazener CM, Pickard R, N'Dow J: Adrenergic drugs for urinary incontinence in adults. Cochrane Database of Systematic Reviews (2003) (2):CD001842.
54. 1A/1L-adrenoceptor partial agonist in women with stress urinary incontinence. Br J Urol Int (2004) 93(1):78-83.
55. Roche/Chugai Creating value in R&D. Chugai Pharmaceutical Co Ltd, Tokyo, Japan (2004). http://www.chugai-pharm.co.jp/html/meeting/pdf/040324e_3.pdf
56. Farre AJ, Figola J: Cizolirtine Citrate. Drugs Future (2002) 27(8):721.
57. Ballet S, Aubel B, Mauborgne A, Polienor H, Farre A, Cesselin F, Hamon M, Bourgoin AS: The novel analgesic, cizolirtine, inhibits the spinal release of substance P and CGRP in rats. Neuropharmacology (2001) 40(4):578-589.
58. R&D Projects: Esteve, Barcelona, Spain. Esteve (2004). http://www.esteve.es/EsteveFront/Proyectos.do?op=Lp&div=id& cm=132
59. Hubbard JW, Nordstrom ST, Smith CP, Brooks KM, Laws-Ricker L, Zhou L, Vargas HM: α-Adrenergic activity and cardiovascular effects of besipirdine HCI (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther (1997) 281 1):337-346.
60. Tang L, Kongsamut S: Frequency-dependent inhibition of neurotransmitter release by besipirdine and HP 184. Eur J Pharmacol (1996) 300(1-2):71-74.
61. Urogene acquires exclusive besipirdine rights from Aventis: Urogene, Evry, France. Urogene SA (2004). http://www.urogene.com/home/pressroom/2004_01_US.pdf
62. Rufford J, Cardozo L, Toozs-Hobson P, Dixon A: HCT1026 -A novel treatment for urgency? 32nd Annual Meeting of International Continence Society, Heidelberg, Germany (2002)32:Abs 225.
63. Nicox Key Products. Nicox, Sophia Artipolis Cedex, France (2004). http://www.nicox.com./pages/eyprods.html
64. Nagabukuro H, Okanishi S, Imai S, Ishichi Y, Ishihara Y, Doi T: Effects of TAK-802, a novel acetylcholinesterase inhibitor, on distension-induced rhythmic bladder contractions in rate and guinea pigs. Eur J Pharmacol (2004) 485(1-3):299-305.
65. Product Pipeline: Takeda Chemical Industries, Osaka, Japan. Takeda Pharmaceutical Co Ltd (2004). http://www.takeda.com/english/product/033q.pdf
66. Deeter J, Frazier J, Staten G, Staszak M, Weigel L: Asymmetric synthesis and absolute stereochemistry of LY248686. Tetrahedron Lett (1990) 31(49):7101-7104.
67. Wender PA, Jesudason CD, Nakahira H, Tamura N, Tebbe AL, Ueno Y: The first synthesis of a daphnane diterpene: The enantiocontrolled total synthesis of resiniferatoxin. J Am Chem Soc (1997) 119 52):12976-12977.
68. 2 receptor agonist. Synthesis and biological evaluation of both the (5R)- and (5S)-enantioisomers of 2-[1-(2-chloro-4-pyrrolidin-1-yl-benzoyl)-2,3,4,5-tetrahydro-1H 1-benzazepin-5-yl]-N-isopropylacetamide. J Med Chem (2002) 45(17): 3805-3808.
69. Giardina GA, Raveglia LF, Grugni M, Sarau HM, Farina C, Medhurst AD, Graziani D, Schmidt DB, Rigolio R, Luttmann M, Cavagnera S et al: Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412). J Med Chem (1999) 42(6):1053-1065.
70. Hueso Rodriguez JA, Berrocal J, Gutierrez B, Farre AJ, Frigola J: Preparation of the enantiomers of the analgesic E-3710. Bioorg Med Chem Lett (1993) 3(2):269-272.
71. Klein JT, Davis L, Olsen GE, Wong GS, Huger FP, Smith CP, Petko WW, Cornfeldt M, Wilker JC, Blitzer RD, Landau E et al: Synthesis and structure-activity relationships of N-propyl-N (4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease. J Mad Chem (1996) 39(2):570-581.